The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome
Open accessAbstract
Prostate cancer is a biologically heterogeneous disease with variable molecular alterations underlying cancer initiation and progression. Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed to improve prognostic accuracy and therapeutic outcomes. In this study, we computationally assembled a large virtual cohort (n = 1,321) of human prostate cancer transcriptome profiles from 38 distinct cohorts and, using pathway activation signatures of known relevance to prostate cancer, developed a novel classification system consisting of three distinct subtypes (named PCS1–3). We validated this subtyping scheme in 10 independent patient cohorts and 19 laboratory models of prostate cancer, including cell lines and genetically engineered mouse models. Analysis of subtype-specific gene expression patterns in independent datasets derived from luminal and basal cell models provides evidence that PCS1 and PCS2 tumors reflect luminal subtypes, while PCS3 represents a basal subtype. We show that PCS1 tumors progress more rapidly to metastatic disease in comparison with PCS2 or PCS3, including PSC1 tumors of low Gleason grade. To apply this finding clinically, we developed a 37-gene panel that accurately assigns individual tumors to one of the three PCS subtypes. This panel was also applied to circulating tumor cells (CTC) and provided evidence that PCS1 CTCs may reflect enzalutamide resistance. In summary, PCS subtyping may improve accuracy in predicting the likelihood of clinical progression and permit treatment stratification at early and late disease stages. Cancer Res; 76(17); 4948–58. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“Currently defined molecular subtypes are based on gene translocations (1,2), gene expression (3,4), mutations (5-8), and oncogenic signatures (9,10).”
BackgroundDirect multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Cited by
Chen, S., Zhu, G., Yang, Y., Wang, F., Xiao, Y.-T., Zhang, N., Bian, X., Zhu, Y., Yu, Y., Liu, F., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-020-00613-6 · Cited by 502
Metastasis Organotropism: Redefining the Congenial Soil
Gao, Y., Bado, I., Wang, H., Zhang, W., Rosen, J. M., & Zhang, X. H.-F. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.012 · Cited by 380
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
Integrative epigenetic taxonomy of primary prostate cancer
Stelloo, S., Nevedomskaya, E., Kim, Y., Schuurman, K., Valle-Encinas, E., Lobo, J., Krijgsman, O., Peeper, D. S., Chang, S. L., Feng, F. Y.-C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07270-2 · Cited by 154
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Iglesias-Gato, D., Thysell, E., Tyanova, S., Crnalic, S., Santos, A., Lima, T. S., Geiger, T., Cox, J., Widmark, A., Bergh, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1229 · Cited by 106
Metadata
- Authors
- You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M., Al-deen Ashab, H., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., Ross, A. E., Schaeffer, E. M., Garraway, I. P., Kim, J., & Freeman, M. R.
- Venue
- Cancer Research
- Published
- 2016-08-31
- Volume
- 76
- Issue
- 17
- Pages
- 4948-4958
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2431963657
- Cited by
- 202
- References
- 6
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-0902
- The paper
- You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M., Al-deen Ashab, H., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., Ross, A. E., Schaeffer, E. M., Garraway, I. P., Kim, J., & Freeman, M. R. (2016). Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-0902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.